This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
Use of dimethyl fumarate
MSMED_DIMETHYL_FUMARATE
No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
326 |
4. Check minimum number of events
Min. number of events
3
|
326 |
5. Include endpointsNone |
326 |
6. Filter based on genotype QC (FinnGen only) |
326 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF2
Similar endpoints
↥List of similar endpoints to
Use of dimethyl fumarate
based on the number of shared cases.
Similar with more cases:
- MS-disease / Multiple Sclerosis
- Demyelinating diseases of the central nervous system
- Autoimmune diseases related-to ILD
- Autoimmune diseases
- Used for control exclusion in common control thyroid runs
Similar with less cases:
None
Case counts by codes
↥Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 326 | 260 | 66 |
| Unadjusted period prevalence (%) | 0.08 | 0.09 | 0.03 |
| Median age at first event (years) | 40.90 | 40.69 | 41.69 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 294
- Matched controls
- 2939
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
109
Kela drug reimbursment
Multiple sclerosis
10110.0
323.0
291
16
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
+∞
323.0
294
13
N07XX09
ATC
[U] dimethyl fumarate; oral
+∞
323.0
294
*
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
12563.2
323.0
288
13
G35
ICD-10 Finland
Multiple sclerosis
+∞
323.0
294
24
L04AX07
ATC
dimethyl fumarate; oral
3584.2
296.9
236
*
L03AB07
ATC
interferon beta-1a; parenteral
1562.9
175.0
153
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
47.9
151.5
194
114
L03AX13
ATC
glatiramer acetate; parenteral
317.1
121.9
116
6
N86
ICPC
Multiple sclerosis
164.6
98.2
99
9
H46
ICD-10 Finland
Optic neuritis
107.1
89.8
95
13
TAB00
NOMESCO Finland
Lumbar puncture
27.1
78.8
112
65
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
136.5
77.5
80
8
L04AA31
ATC
teriflunomide; oral
316.2
74.0
72
*
L03AB08
ATC
interferon beta-1b; parenteral
224.2
69.4
69
*
XA800
NOMESCO Finland
Neuropsychological investigation
23.9
55.6
81
46
2AB04
NOMESCO Finland
NA
639.9
55.5
53
*
164
Kela drug reimbursment
Fingolimod
153.5
49.5
51
*
N04BB01
ATC
amantadine; oral
43.7
44.0
54
15
353
Kela drug reimbursment
Cladribine and fingolimod
167.1
42.0
43
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
25.9
40.7
57
27
XCK00
NOMESCO Finland
Perimetry
14.2
38.5
68
61
ZX120
NOMESCO Finland
Intravenous
10.1
38.5
82
108
L04AA27
ATC
fingolimod; oral
204.3
35.6
36
*
G04BD12
ATC
mirabegron; oral
14.2
34.9
61
53
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
30.2
33.0
44
17
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
8.1
32.3
79
128
XKD00
NOMESCO Finland
Uroflowmetry
11.6
31.6
61
65
XKD06
NOMESCO Finland
Physiologic investigation of micturition
27.8
31.6
43
18
N06BA07
ATC
modafinil; oral
76.5
30.6
34
5
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
335.0
30.4
30
*
M03BX01
ATC
baclofen; systemic
24.1
28.3
40
19
G04BD09
ATC
trospium; oral
33.6
25.6
33
11
R1250
NOMESCO Finland
Evaluation of functional capability
18.8
24.8
38
23
R20.2
ICD-10 Finland
Paraesthesia of skin
7.2
24.5
63
107
Z01.0
ICD-10 Finland
Examination of eyes and vision
5.1
23.3
83
211
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
19.1
22.4
34
20
L03AB13
ATC
peginterferon beta-1a; parenteral
+∞
21.1
20
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.8
20.9
63
131
TKC22
NOMESCO Finland
Catheterisation instruction
38.8
20.2
25
7
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
11.9
20.1
37
35
H02AB04
ATC
methylprednisolone; systemic
4.5
19.4
76
210
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
8.7
19.2
42
55
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
22.6
17.6
25
12
R4110
NOMESCO Finland
Physiotherapy
3.3
16.2
100
397
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
6.6
15.3
40
68
G04BD08
ATC
solifenacin; oral
9.3
14.1
29
34
R4150
NOMESCO Finland
Neuropsychological rehabilitation
21.3
14.0
20
10
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
78.9
13.7
15
*
H48.1*G35
ICD-10 Finland
Retrobulbar neuritis in multiple sclerosis
+∞
13.6
13
*
C10AC01
ATC
colestyramine; oral
10.5
13.5
26
27
4AA23
NOMESCO Finland
NA
73.1
12.7
14
*
UKC02
NOMESCO Finland
Cystoscopy
4.5
12.4
45
113
3400A
ICD-9 Finland
Multiple sclerosis[SCLEROSIS MULTIPLEX (DISSEMINATA)]
+∞
11.5
11
*
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
36.6
11.4
14
*
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
26.2
11.3
15
6
N05CF01
ATC
zopiclone; oral
2.6
11.2
96
457
XCW99
NOMESCO Finland
Other investigative procedure of eye
4.1
11.2
45
125
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
5.0
11.1
36
80
H53.2
ICD-10 Finland
Diplopia
10.2
10.9
21
22
XCD10
NOMESCO Finland
Electrophysiological examination of eye
10.2
10.9
21
22
NA7BG
NOMESCO Finland
Spine and spinal cord MRI examination with high intensity magnet
18.7
10.8
16
9
XKC03
NOMESCO Finland
Water cystometry
8.5
10.8
23
29
G04BD11
ATC
fesoterodine; oral
22.5
10.8
15
7
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
8.7
10.5
22
27
G04BD07
ATC
tolterodine; oral
8.7
10.5
22
27
R35
ICD-10 Finland
Polyuria
7.6
10.5
24
34
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
19.7
10.4
15
8
G04BD04
ATC
oxybutynin; oral, transdermal
7.0
10.0
24
37
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
7.8
9.9
22
30
G37.3
ICD-10 Finland
Acute transverse myelitis in demyelinating disease of central nervous system
+∞
9.4
9
*
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
8.4
9.0
19
24
N03AX12
ATC
gabapentin; oral
2.9
8.9
57
222
R4120
NOMESCO Finland
Occupational therapy
4.5
8.7
30
72
TAB22
NOMESCO Finland
Stoppin epidural fluid escape with coagulated blood
7.7
8.6
19
26
H53.1
ICD-10 Finland
Subjective visual disturbances
4.4
8.3
29
71
N29
ICPC
Neurological sympt/complt other
8.5
8.2
17
21
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
3.9
8.2
33
92
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
5.1
8.2
25
53
AA1BM
NOMESCO Finland
MRI examination of brain with 3 Tesla magnet
17.8
8.1
12
7
O99.3
ICD-10 Finland
Mental disorders and diseases of the nervous system complicating pregnancy, childbirth and the puerperium
4.8
8.1
26
58
N31.8
ICD-10 Finland
Other neuromuscular dysfunction of bladder
46.2
7.8
9
*
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
4.3
7.7
28
71
N03AE01
ATC
clonazepam; systemic
4.0
7.6
30
82
G04CA02
ATC
tamsulosin; oral
4.4
7.4
26
64
4AA36
NOMESCO Finland
NA
+∞
7.3
7
*
N32.83
ICD-10 Finland
Nozzle synergy in the bladder neck
30.8
7.2
9
*
N03AX16
ATC
pregabalin; oral
2.3
7.0
73
371
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.5
6.8
31
97
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.7
6.5
47
196
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
71.3
6.5
7
*
R03CA02
ATC
ephedrine; oral
71.3
6.5
7
*
L04AA40
ATC
cladribine; oral
71.3
6.5
7
*
NA7CM
NOMESCO Finland
Spine and spinal cord extensive MRI examination with 3 Tesla magnet
+∞
6.3
6
*
L01BB04
ATC
cladribine; systemic
+∞
6.3
6
*
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
27.3
6.3
8
*
G95.8
ICD-10 Finland
Other specified diseases of spinal cord
27.3
6.3
8
*
L28
ICPC
Limited function/disability (L)
3.1
6.2
32
110
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
93
55
23.26
117.16
1.2
1.1
—
—
—
0
0
233
699
9.18
84.57
5.2
2.6
—
—
—
0
0
301
1282
18.58
74.23
20.2
5.1
62.1
56.5
%
21.84
301
1217
302
1292
19.17
74.12
20.6
5.3
23.6
29.7
%
28.20
302
1230
189
549
6.81
67.42
4.7
2.2
0.1
0.3
e6/l
3.65
182
398
75
81
11.73
65.40
1.8
1.7
0.0
0.0
iu/ml
—
6
11
41
16
29.17
59.74
2.6
2.9
15.2
11.9
%
0.40
25
11
37
16
25.96
51.79
2.6
2.9
—
—
—
0
0
118
299
5.62
46.43
3.6
2.1
0.7
0.9
e6/l
0.54
79
157
30
21
15.63
33.50
1.0
1.0
—
—
—
0
0
100
285
4.62
32.99
3.9
2.1
2.8
3.7
e6/l
0.52
61
143
217
1076
4.04
32.30
2.4
2.2
94.8
72.1
nmol/l
18.58
209
1015
35
37
10.48
30.27
1.1
1.0
—
—
—
0
0
27
22
13.29
27.57
5.0
1.6
807.3
729.9
e6/l
—
15
7
228
1249
3.75
27.43
7.8
4.0
0.0
0.0
estimate
0.50
47
258
227
1245
3.71
27.15
5.9
2.8
0.0
0.0
estimate
0.00
47
256
228
1259
3.70
26.87
5.8
2.9
0.0
0.0
estimate
0.00
48
252
51
111
5.26
22.84
1.3
1.3
—
—
—
0
0
27
30
9.72
22.39
1.0
1.1
—
—
—
0
0
22
18
13.03
22.29
1.1
1.1
1786.6
1720.3
miu/ml
0.07
22
18
27
33
8.83
20.81
1.0
1.1
—
—
—
0
0
22
21
11.16
20.21
1.0
1.1
0.9
1.1
u/l
—
5
12
26
33
8.47
19.43
1.0
1.1
—
—
—
0
0
326
2870
+∞
16.88
13.8
9.6
62.9
68.4
umol/l
14.30
326
2870
30
68
4.76
12.66
1.0
1.2
17.5
222.7
e6/l
1.08
25
54
30
68
4.76
12.66
1.0
1.1
13.8
4.6
e6/l
1.75
24
51
16
7
23.93
11.68
5.3
2.1
—
—
—
0
0
53
196
3.03
11.05
2.8
1.6
—
—
—
0
0
208
2579
0.47
9.42
2.7
3.0
1.2
1.2
mmol/l
0.42
196
2465
23
54
4.51
9.28
3.8
3.6
3.4
4.4
e9/l
1.71
23
54
23
55
4.42
9.07
3.9
3.7
61.2
58.3
%
0.63
23
55
145
928
2.01
8.59
3.7
3.0
26.0
28.2
u/l
0.62
137
890
292
2437
2.90
8.47
25.2
11.3
13.2
13.4
%
2.02
292
2399
223
2676
0.47
8.47
3.0
3.3
1.6
1.5
mmol/l
3.10
205
2566
227
2705
0.47
8.37
3.1
3.6
3.0
2.9
mmol/l
0.36
210
2585
172
1189
1.95
7.97
3.6
4.9
9.1
10.0
umol/l
0.98
165
1125
227
2683
0.49
7.43
3.0
3.4
4.9
4.8
mmol/l
1.08
212
2577
293
2500
2.70
7.18
9.8
7.7
103.4
94.5
ml/min/173m2
20.80
270
2035
53
247
2.37
6.92
2.8
2.2
2289.4
2837.6
u/l
—
6
103
145
992
1.83
6.55
7.1
2.9
—
—
—
0
0
10
8
12.84
6.12
1.0
1.7
—
—
—
0
0
8
5
16.34
5.43
1.8
3.4
—
—
—
0
0
326
3149
+∞
4.48
30.0
14.3
137.4
136.3
g/l
1.11
326
3122
97
648
1.71
4.42
8.7
3.2
0.0
0.0
estimate
0.80
47
256
164
1263
1.60
4.21
3.1
3.8
6.2
6.3
mmol/l
0.44
154
1127
115
855
1.53
3.24
3.2
3.9
39.0
37.5
g/l
2.33
104
807
219
1870
1.52
3.12
4.3
6.2
67.6
71.9
u/l
1.56
207
1772
300
2771
2.04
3.12
9.4
9.3
21.0
18.2
mg/l
0.61
199
2089
286
2609
1.78
2.99
7.7
8.8
3.9
3.9
mmol/l
0.26
277
2529
285
2600
1.76
2.95
7.6
8.7
139.9
139.6
mmol/l
1.90
278
2532
202
2294
0.69
2.69
3.0
4.0
36.7
37.6
mmol/mol
0.78
193
2199
44
270
1.73
2.67
2.3
2.2
5.1
6.2
umol/l
0.32
34
233
9
25
3.67
2.59
1.0
1.6
—
—
—
0
0
226
2486
0.70
2.17
2.5
3.3
5.5
5.6
mmol/l
0.84
215
2346
14
274
0.49
1.90
1.2
1.5
—
—
—
0
0
7
25
2.84
1.66
1.0
1.1
—
—
—
0
0
7
25
2.84
1.66
1.0
1.1
—
—
—
0
0
96
772
1.35
1.61
1.4
1.5
—
—
—
0
0
7
26
2.73
1.59
1.0
1.1
—
—
—
0
0
7
26
2.73
1.59
1.0
1.1
—
—
—
0
0
7
26
2.73
1.59
1.0
1.1
—
—
—
0
0
10
205
0.47
1.57
1.5
1.4
—
—
—
0
0
26
397
0.63
1.50
1.2
1.5
—
—
—
0
0
13
234
0.54
1.40
1.3
1.4
—
—
—
0
0
13
234
0.54
1.40
1.3
1.4
—
—
—
0
0
13
233
0.54
1.38
1.3
1.4
—
—
—
0
0
13
233
0.54
1.38
1.3
1.4
—
—
—
0
0
17
99
1.76
1.30
1.5
1.4
22.1
21.0
u/l
0.05
12
83
8
159
0.49
1.28
1.8
1.7
—
—
—
0
0
15
247
0.59
1.20
1.4
1.5
—
—
—
0
0
107
1245
0.79
1.19
3.4
3.8
—
—
—
0
0
10
184
0.53
1.17
1.6
1.5
—
—
—
0
0
40
526
0.73
1.09
1.3
1.3
2.1
9.0
u/ml
2.17
16
234
234
2484
0.79
1.06
3.4
3.9
—
—
—
0
0
7
133
0.52
1.01
1.1
1.5
—
—
—
0
0
129
1448
0.82
0.98
2.4
2.9
102.7
65.8
ug/l
0.68
121
1387
9
153
0.58
0.91
2.6
1.9
—
—
—
0
0
83
716
1.21
0.77
1.7
2.8
2.4
2.3
mmol/l
0.45
76
664
0
28
0.00
0.76
0.0
1.8
—
—
—
0
0
284
2741
1.28
0.76
22.9
9.9
41.2
40.5
%
2.77
236
2339
14
205
0.67
0.72
1.9
5.4
0.9
1.0
mmol/l
0.96
14
190
7
40
1.77
0.71
1.0
1.2
—
—
—
0
0
7
40
1.77
0.71
1.0
1.2
—
—
—
0
0
28
214
1.34
0.69
2.4
2.2
25.1
33.8
u/l
1.11
22
185
49
586
0.81
0.68
1.9
1.8
—
—
—
0
0
23
172
1.36
0.65
1.3
1.7
—
—
—
0
0
267
2571
1.21
0.65
4.6
4.7
1.7
2.1
mu/l
0.55
255
2463
5
29
1.74
0.64
1.2
1.4
—
—
—
0
0
24
182
1.34
0.63
1.3
1.3
118.2
260.2
miu/ml
—
10
92
14
96
1.48
0.62
1.1
1.3
—
—
—
0
0
8
50
1.61
0.61
1.0
2.3
2.5
2.9
g/l
—
8
41
0
21
0.00
0.60
0.0
1.3
—
—
—
0
0
8
52
1.55
0.60
1.0
2.3
6.1
6.9
g/l
—
8
44
8
52
1.55
0.60
1.0
2.3
3.3
3.7
g/l
—
8
40
8
52
1.55
0.60
1.0
2.3
—
—
—
0
0
8
55
1.47
0.56
1.0
1.3
—
110.2
—
0
15
10
65
1.56
0.56
1.0
1.2
—
—
—
0
0
52
604
0.83
0.55
1.6
1.7
0.5
0.7
mg/l
0.53
40
443
9
134
0.66
0.53
1.0
1.6
—
—
—
0
0
18
235
0.75
0.51
3.3
3.3
28.0
31.3
%
0.76
13
178
9
65
1.40
0.51
1.0
1.2
—
—
—
0
0
7
106
0.65
0.49
1.1
1.6
—
—
—
0
0
7
106
0.65
0.49
1.1
2.8
4.8
5.1
kpa
—
7
100
47
545
0.84
0.49
1.8
2.0
2.7
2.9
mg/l
0.23
37
486
8
119
0.66
0.46
2.1
1.8
—
—
—
0
0
35
414
0.83
0.46
1.6
1.6
—
—
—
0
0
37
435
0.83
0.45
1.7
1.8
—
—
—
0
0
48
417
1.18
0.44
1.3
1.6
551.5
58441978.6
pmol/l
1.07
43
385
5
31
1.62
0.43
1.6
2.0
—
—
—
0
0
21
167
1.28
0.43
1.3
1.7
—
—
—
0
0
13
96
1.37
0.42
2.2
2.0
8.6
6.8
iu/l
—
5
37
0
15
0.00
0.41
0.0
1.8
—
—
—
0
0
0
15
0.00
0.41
0.0
1.0
—
—
—
0
0
0
15
0.00
0.41
0.0
1.8
—
—
—
0
0
0
15
0.00
0.41
0.0
1.8
—
—
—
0
0
0
15
0.00
0.41
0.0
1.8
—
—
—
0
0
0
16
0.00
0.41
0.0
1.6
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
16
0.00
0.41
0.0
2.5
—
117.9
—
0
16
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
40
345
1.18
0.40
1.7
2.7
15.1
492.0
ng/l
1.09
15
170
47
532
0.86
0.38
1.2
1.3
11.5
24.2
iu/ml
—
8
172
55
615
0.87
0.38
1.5
1.6
1.6
1.4
mmol/l
0.43
46
554
6
43
1.40
0.35
1.2
1.7
—
—
—
0
0
6
43
1.40
0.35
1.0
1.0
—
—
—
0
0
80
735
1.12
0.34
1.3
1.3
0.5
2.4
u/ml
1.67
14
200
6
46
1.31
0.33
1.2
1.7
—
—
—
0
0
79
854
0.90
0.32
4.9
4.8
1.2
1.2
mmol/l
0.30
71
793
83
769
1.11
0.31
1.5
1.7
100.4
97.7
pmol/l
0.19
42
447
7
56
1.26
0.29
1.0
1.3
—
1.2
—
0
6
7
56
1.26
0.29
1.1
1.6
—
—
—
0
0
8
109
0.73
0.29
1.4
1.6
1.1
1.2
g/l
—
8
103
30
343
0.86
0.29
1.7
1.7
—
—
—
0
0
22
187
1.19
0.27
1.5
1.4
—
—
—
0
0
46
417
1.12
0.26
1.4
1.4
19.0
20.9
nmol/l
0.44
41
377
23
198
1.17
0.25
1.0
1.0
—
—
—
0
0
34
304
1.13
0.24
1.7
2.0
16.4
15.7
umol/l
0.19
29
283
20
232
0.85
0.23
5.1
4.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
2.1
—
—
—
0
0
0
10
0.00
0.21
0.0
2.1
—
—
—
0
0
0
10
0.00
0.21
0.0
3.4
—
127.5
—
0
10
0
10
0.00
0.21
0.0
2.1
—
—
—
0
0
0
10
0.00
0.21
0.0
2.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
78
827
0.93
0.21
1.6
1.6
—
—
—
0
0
199
1938
1.07
0.21
2.3
3.4
6.7
8.3
mm/h
2.66
185
1832
0
12
0.00
0.21
0.0
1.1
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
13
0.00
0.21
0.0
1.0
—
147.2
—
0
13
0
13
0.00
0.21
0.0
1.0
—
95.3
—
0
6
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
115.7
—
0
6
0
14
0.00
0.20
0.0
1.4
—
—
—
0
0
68
723
0.92
0.20
2.0
2.1
—
—
—
0
0
65
692
0.92
0.20
1.6
2.5
211.8
17.6
ng/l
0.62
27
278
6
53
1.13
0.19
1.5
1.4
—
—
—
0
0
92
964
0.94
0.18
5.2
5.5
1.2
1.2
mmol/l
1.05
81
823
15
174
0.86
0.18
1.2
2.4
0.2
0.2
g/l
0.16
15
168
12
101
1.20
0.17
1.1
1.4
—
—
—
0
0
20
177
1.14
0.16
1.5
1.9
91.8
80.7
ml/min/173m2
—
5
62
27
296
0.90
0.15
1.3
1.2
72.8
185.1
iu/ml
—
9
122
62
652
0.94
0.14
1.8
1.9
—
—
—
0
0
23
252
0.91
0.13
1.8
2.0
25.4
25.9
%
0.04
16
219
29
268
1.09
0.12
1.4
1.8
—
—
—
0
0
11
95
1.16
0.12
1.1
1.1
—
—
—
0
0
14
155
0.90
0.09
1.4
1.5
—
—
—
0
0
5
60
0.83
0.08
1.2
1.1
—
—
—
0
0
5
63
0.79
0.08
1.0
1.1
—
—
—
0
0
7
64
1.10
0.08
1.4
2.9
53.8
55.7
%
—
7
64
7
64
1.10
0.08
2.7
1.8
—
—
—
0
0
23
215
1.08
0.08
1.8
3.1
20.2
22.9
%
—
10
59
6
74
0.81
0.07
1.3
1.9
—
—
—
0
0
8
76
1.05
0.07
1.0
1.6
—
—
—
0
0
9
84
1.07
0.07
1.1
1.2
—
29.2
—
0
15
17
183
0.93
0.06
1.8
2.6
—
—
—
0
0
14
152
0.92
0.06
12.9
7.4
2.5
0.9
mmol/l
—
6
112
220
2218
0.98
0.05
4.0
4.2
14.6
14.3
pmol/l
1.21
207
2108
71
723
0.98
0.03
1.7
2.2
50.3
54.6
u/l
0.84
64
681
12
126
0.95
0.00
3.4
3.6
72.0
74.2
ng/l
0.05
12
118
10
103
0.97
0.00
1.1
2.3
—
—
—
0
0
16
163
0.98
0.00
1.8
2.0
0.6
0.6
ug/l
—
8
66
15
154
0.97
0.00
12.3
7.3
12.9
13.8
kpa
0.22
15
147
15
154
0.97
0.00
12.3
7.3
5.1
5.1
kpa
0.01
15
146
0
8
0.00
0.00
0.0
2.0
—
—
—
0
0
6
60
1.00
0.00
1.8
1.8
13.0
13.2
%
—
6
60
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
203.1
—
0
8
0
8
0.00
0.00
0.0
1.0
—
114.4
—
0
8
7
79
0.88
0.00
1.4
2.1
—
—
—
0
0
0
5
0.00
0.00
0.0
2.2
—
—
—
0
0
8
79
1.01
0.00
1.6
2.3
89.2
62.6
ng/l
—
8
71
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
2.0
—
7.2
—
0
9
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
1.2
—
0
5
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
6.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
8
88
0.91
0.00
1.8
5.0
25.7
24.7
mmol/l
—
8
88
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
17.0
—
0
6
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.4
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: MSMED_DIMETHYL_FUMARATE – Use of dimethyl fumarate
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).